BRPI0510063A - plasmina modificada recombinantemente - Google Patents

plasmina modificada recombinantemente

Info

Publication number
BRPI0510063A
BRPI0510063A BRPI0510063-1A BRPI0510063A BRPI0510063A BR PI0510063 A BRPI0510063 A BR PI0510063A BR PI0510063 A BRPI0510063 A BR PI0510063A BR PI0510063 A BRPI0510063 A BR PI0510063A
Authority
BR
Brazil
Prior art keywords
domain
recombinantly modified
terminal
human plasminogen
polypeptide
Prior art date
Application number
BRPI0510063-1A
Other languages
English (en)
Inventor
Jennifer Audrey Hunt
Valery Novokhatny
Original Assignee
Talecris Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34982338&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0510063(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Talecris Biotherapeutics Inc filed Critical Talecris Biotherapeutics Inc
Publication of BRPI0510063A publication Critical patent/BRPI0510063A/pt
Publication of BRPI0510063B1 publication Critical patent/BRPI0510063B1/pt
Publication of BRPI0510063B8 publication Critical patent/BRPI0510063B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PLASMINA MODIFICADA RECOMBINANTEMENTE. A presente invenção refere-se aos polinucleotídeos e polipeptídeos que se referem a uma molécula de plasmin (ogênio) modificada recombinantemente. A molécula de plasmin (ogênio) tem um domínio simples de kringle N-terminal ao sítio de ativação presente na molécula de plasminogênio humano nativo e exibe ligação com usina e características enzimáticas significativas associadas com a enzima nativa.
BRPI0510063A 2004-04-22 2005-04-21 plasmina recombinante modificada, polinucleotídeo codificando a mesma, vetor de expressão e micro-organismo transgênico BRPI0510063B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56447204P 2004-04-22 2004-04-22
US60/564,472 2004-04-22
PCT/US2005/013562 WO2005105990A2 (en) 2004-04-22 2005-04-21 Recombinantly modified plasmin

Publications (3)

Publication Number Publication Date
BRPI0510063A true BRPI0510063A (pt) 2008-03-11
BRPI0510063B1 BRPI0510063B1 (pt) 2020-03-17
BRPI0510063B8 BRPI0510063B8 (pt) 2021-05-25

Family

ID=34982338

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510063A BRPI0510063B8 (pt) 2004-04-22 2005-04-21 plasmina recombinante modificada, polinucleotídeo codificando a mesma, vetor de expressão e micro-organismo transgênico

Country Status (28)

Country Link
US (2) US8034913B2 (pt)
EP (2) EP1740698B1 (pt)
JP (1) JP5026254B2 (pt)
KR (1) KR101161819B1 (pt)
CN (2) CN102660564B (pt)
AT (1) ATE476502T1 (pt)
AU (1) AU2005238464B2 (pt)
BR (1) BRPI0510063B8 (pt)
CA (1) CA2563675C (pt)
CY (1) CY1111650T1 (pt)
DE (1) DE602005022692D1 (pt)
DK (1) DK1740698T3 (pt)
EA (1) EA010784B1 (pt)
ES (2) ES2534744T3 (pt)
HK (3) HK1099341A1 (pt)
HR (1) HRP20100568T1 (pt)
IL (1) IL178343A (pt)
MA (1) MA28590B1 (pt)
MX (1) MXPA06012236A (pt)
NO (1) NO338542B1 (pt)
NZ (1) NZ550250A (pt)
PL (2) PL2246417T3 (pt)
PT (2) PT1740698E (pt)
RS (1) RS51623B (pt)
SI (1) SI1740698T1 (pt)
TN (1) TNSN06332A1 (pt)
WO (1) WO2005105990A2 (pt)
ZA (1) ZA200608498B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2555609A1 (en) 2004-02-11 2005-08-25 Biolex, Inc. Expression of plasminogen and microplasminogen in duckweed
KR101161819B1 (ko) 2004-04-22 2012-07-03 테일크리스 바이오쎄러퓨틱스 아이엔씨. 재조합적으로 변형된 플라스민
US8231869B2 (en) * 2005-10-20 2012-07-31 Grifols Therapeutics Inc. Recombinant plasmin for opthalmic indications
KR100888022B1 (ko) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
EP2220221B1 (en) * 2007-11-29 2014-12-31 Grifols Therapeutics Inc. Recombinantly modified plasmin
BRPI0913397B8 (pt) 2008-06-04 2021-05-25 Grifols Therapeutics Inc método para preparar plasmina
JP5789521B2 (ja) 2009-03-03 2015-10-07 グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． プラスミノーゲンを製造するための組成物、方法およびキット；ならびにそれから製造されるプラスミン
MX2012000475A (es) 2009-07-10 2012-03-26 Thrombogenics Nv Variantes de plasminogeno y plasmina.
EP2480249B1 (en) 2009-08-28 2015-01-28 ThromboGenics N.V. Plasmin for the treatment of filtration failure after trabeculectomy
EP2661493B1 (en) 2011-01-05 2016-03-30 ThromboGenics N.V. Plasminogen and plasmin variants
CN103764163A (zh) 2011-08-12 2014-04-30 斯路姆基因公司 纤溶酶原和纤溶酶变体
US10709771B2 (en) * 2015-12-18 2020-07-14 Talengen International Limited Method for preventing or treating diabetic retinopathy
WO2018107686A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种治疗动脉粥样硬化及其并发症的方法
JP7168990B2 (ja) 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物
CN108210904A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 治疗动脉粥样硬化及其并发症的药物及其用途
WO2018107705A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种促进胰岛素分泌的方法
CN115427704A (zh) 2020-04-13 2022-12-02 株式会社F.C.C. 动力传递装置
CN115697385A (zh) * 2020-05-11 2023-02-03 泰伦基国际有限公司 一种治疗脊髓性肌萎缩症的方法和药物
US20240299506A1 (en) 2020-11-25 2024-09-12 Grifols Worldwide Operations Limited Wound healing
US11964004B2 (en) * 2021-03-31 2024-04-23 Shenzhen Bay Laboratory Short in vivo half-life and in vivo unstable recombinant microplasmin, pharmaceutical composition comprising thereof and method of treating thromboembolism related diseases including administration thereof
WO2024018051A1 (en) 2022-07-22 2024-01-25 Grifols Worldwide Operations Limited Stable plasmin compositions for organ preservation and reconditioning

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652639A (en) 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US5149533A (en) * 1987-06-04 1992-09-22 Zymogenetics, Inc. Modified t-PA with kringle-/replaced by another kringle
US4774087A (en) 1987-08-14 1988-09-27 Northwestern University Micro-size fibrinolytic plasmin
ES2120949T4 (es) 1990-06-28 2011-12-29 Sanofi-Aventis Deutschland Gmbh 50% Proteinas de fusión con porciones de inmunoglobulinas, su preparación y empleo.
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
US6613508B1 (en) 1996-01-23 2003-09-02 Qiagen Genomics, Inc. Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques
US6312893B1 (en) 1996-01-23 2001-11-06 Qiagen Genomics, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
DE69701671T3 (de) 1996-01-23 2006-08-17 Qiagen Genomics, Inc., Bothell Verfahren und zusammenstellungen zur sequenzbestimmung von nukleinsäuremolekülen
JPH10158300A (ja) 1996-11-28 1998-06-16 Suzuki Motor Corp 血管新生抑制効果を有するタンパク質とその製造方法及びアンギオスタチンの製造方法
EP1000176A1 (en) 1997-07-22 2000-05-17 Rapigene, Inc. Computer method and system for correlating sequencing data by ms
US6538103B1 (en) 1998-07-14 2003-03-25 Bristol--Myers Squibb Company Lysine binding fragments of angiostatin
DK1117437T3 (da) 1998-09-29 2007-04-10 Leuven Res & Dev Vzw Anvendelse af forbindelser, der reducerer alfa2-antiplasmin in vivo, til fremstilling af en sammensætning til behandling af iskæmiske slagtilfælde
US6969515B2 (en) 1999-11-13 2005-11-29 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US6355243B1 (en) 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
JP2004509609A (ja) 2000-06-02 2004-04-02 ブルー　ヘロン　バイオテクノロジー　インコーポレイテッド 合成二本鎖オリゴヌクレオチドの配列忠実度を改善するための方法
AU2002218890A1 (en) 2000-12-21 2002-07-01 Thromb-X N.V. A yeast expression vector and a method of making a recombinant protein by expression in a yeast cell
AU2002357249A1 (en) 2001-12-13 2003-07-09 Blue Heron Biotechnology, Inc. Methods for removal of double-stranded oligonucleotides containing sequence errors using mismatch recognition proteins
US7776026B2 (en) 2002-02-06 2010-08-17 Nuvue Technologies, Inc. Method for vitreous liquefaction
US20050124036A1 (en) 2002-02-06 2005-06-09 Rudy Susilo Method for producing recombinant proteins in micro-organisms
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
KR101161819B1 (ko) 2004-04-22 2012-07-03 테일크리스 바이오쎄러퓨틱스 아이엔씨. 재조합적으로 변형된 플라스민
US8231869B2 (en) 2005-10-20 2012-07-31 Grifols Therapeutics Inc. Recombinant plasmin for opthalmic indications
EP2220221B1 (en) * 2007-11-29 2014-12-31 Grifols Therapeutics Inc. Recombinantly modified plasmin

Also Published As

Publication number Publication date
ZA200608498B (en) 2008-07-30
DK1740698T3 (da) 2010-10-25
IL178343A (en) 2010-11-30
EP2246417A1 (en) 2010-11-03
EP1740698A2 (en) 2007-01-10
EA010784B1 (ru) 2008-10-30
HK1150242A1 (en) 2011-11-11
US8034913B2 (en) 2011-10-11
EP1740698B1 (en) 2010-08-04
US20110318812A1 (en) 2011-12-29
EP2246417B1 (en) 2015-01-21
HRP20100568T1 (hr) 2010-11-30
WO2005105990A3 (en) 2006-01-12
CA2563675C (en) 2012-08-28
BRPI0510063B8 (pt) 2021-05-25
ATE476502T1 (de) 2010-08-15
TNSN06332A1 (en) 2008-02-22
EA200601950A1 (ru) 2007-02-27
PT1740698E (pt) 2010-11-02
ES2534744T3 (es) 2015-04-28
PL2246417T3 (pl) 2015-06-30
CN1961070A (zh) 2007-05-09
CY1111650T1 (el) 2015-10-07
IL178343A0 (en) 2007-02-11
JP2007533327A (ja) 2007-11-22
KR101161819B1 (ko) 2012-07-03
PL1740698T3 (pl) 2011-01-31
HK1099341A1 (en) 2007-08-10
MXPA06012236A (es) 2007-01-31
US8420079B2 (en) 2013-04-16
CA2563675A1 (en) 2005-11-10
BRPI0510063B1 (pt) 2020-03-17
DE602005022692D1 (de) 2010-09-16
SI1740698T1 (sl) 2010-11-30
US20100304465A1 (en) 2010-12-02
NZ550250A (en) 2009-05-31
NO20065050L (no) 2006-11-03
AU2005238464B2 (en) 2011-01-27
CN102660564B (zh) 2013-05-08
JP5026254B2 (ja) 2012-09-12
KR20070006918A (ko) 2007-01-11
PT2246417E (pt) 2015-05-05
HK1175812A1 (en) 2013-07-12
WO2005105990A2 (en) 2005-11-10
ES2349555T3 (es) 2011-01-05
MA28590B1 (fr) 2007-05-02
CN102660564A (zh) 2012-09-12
AU2005238464A1 (en) 2005-11-10
RS51623B (en) 2011-08-31
NO338542B1 (no) 2016-09-05

Similar Documents

Publication Publication Date Title
EA200601950A1 (ru) Рекомбинантно модифицированный плазмин
NZ593837A (en) Recombinantly modified plasmin
Bode The structure of thrombin: a janus-headed proteinase
MY148447A (en) Method for amidating polypeptides with basic aminoacid d-terminals by means of specific endoproteases
Hata et al. Domain II of m-calpain is a Ca2+-dependent cysteine protease
BRPI0606612A2 (pt) expressão recombinante de proteìnas em uma forma de duas cadeias ligadas por dissulfeto
TW200733970A (en) Recombinantly modified plasmin
WO2007016476A3 (en) Hepatitis c serine protease inhibitors and uses therefor
ATE463512T1 (de) Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
DE602006017331D1 (de) Kontrollierte produktion und zuführung biologisch aktiver stoffe durch darmbakterien
ATE548380T1 (de) Mutante des hgf-precursor-proteins und aktivierte form davon
Hahn et al. Purification and characterization of a serine protease with fibrinolytic activity from Tenodera sinensis (praying mantis)
ATE277172T1 (de) Rekombinante blutgerinnungsproteasen
Ribeiro de Queiroz et al. Purification and characterization of BmooAi: a new toxin from Bothrops moojeni snake venom that inhibits platelet aggregation
HUP0400458A2 (hu) Kobalaminkötő fehérjéket expresszáló transzgenikus növények
Castro et al. Current status of snake venom thrombin-like enzymes
DE60336265D1 (de) Inhibitoren der enzymaktivität der endooligopeptidase a (eopa) und ihre verwendungen
NO20082864L (no) Nytt polypeptid med esteraseaktivitet og rekombinant esterase samt anvendelse derav
Oyama et al. Amino acid sequence of a thrombin like enzyme, elegaxobin II, from the venom of Trimeresurus elegans (Sakishima-Habu)
WO2003085377A3 (en) Novel pancortin-pablo protein interactions and methods of use thereof
ATE460476T1 (de) Menschliche protein phosphatase mit ef-hände-1 (ppef-1)- ähnliches genvariant assoziert mit t- zellen lymphoblastisches lymphom
Yamakawa Bitis arietans hemorrhagic proteinases
Le Bonniec STRUCTURE–FUNCTION RELATIONSHIP IN THE PLASMINOGEN ACTIVATOR ISOLATED FROM THE VENOM OF TRIMERESURUS STEJNEGERI

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: GRIFOLS THERAPEUTICS INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C12N 9/68 , C12N 15/57 , C12N 5/10

Ipc: C12N 9/68 (2006.01), C12N 15/57 (2006.01), C12N 5/

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/03/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/04/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2771 DE 15-02-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.